Publicaciones en colaboración con investigadores/as de University of Lorraine (44)

2024

  1. EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 7, pp. 1891-1908

  2. Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial

    Hypertension Research

  3. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

    Heart, Vol. 110, Núm. 19, pp. 1180-1187

2023

  1. Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial

    JHEP Reports, Vol. 5, Núm. 5

  2. Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study

    Circulation: Heart Failure, Vol. 16, Núm. 5, pp. E009694

  3. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials

    International Journal of Cardiology, Vol. 377, pp. 86-88

  4. The Psychological Science Accelerator's COVID-19 rapid-response dataset

    Scientific data, Vol. 10, Núm. 1, pp. 87

2022

  1. A global experiment on motivating social distancing during the COVID-19 pandemic

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, Núm. 22

  2. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331

  3. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 24, Núm. 6, pp. 927-943

  4. Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 24, Núm. 6, pp. 944-958

  5. Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial

    ESC Heart Failure, Vol. 9, Núm. 6, pp. 4352-4357

  6. Erratum: A global experiment on motivating social distancing during the COVID-19 pandemic (Proceedings of the National Academy of Sciences of the United States of America (2022) 119 (e2111091119) DOI: 10.1073/pnas.2111091119)

    Proceedings of the National Academy of Sciences of the United States of America

  7. Erratum: Author Correction: A multi-country test of brief reappraisal interventions on emotions during the COVID-19 pandemic (Nature human behaviour (2021) 5 8 (1089-1110))

    Nature human behaviour

  8. In COVID-19 Health Messaging, Loss Framing Increases Anxiety with Little-to-No Concomitant Benefits: Experimental Evidence from 84 Countries

    Affective Science, Vol. 3, Núm. 3, pp. 577-602

  9. Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial

    European Journal of Heart Failure, Vol. 24, Núm. 5, pp. 771-778

  10. The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial

    European Journal of Heart Failure, Vol. 24, Núm. 9, pp. 1559-1568

2021

  1. A multi-country test of brief reappraisal interventions on emotions during the COVID-19 pandemic

    Nature Human Behaviour, Vol. 5, Núm. 8, pp. 1089-1110

  2. Identification of sex-specific biomarkers predicting new-onset heart failure

    ESC Heart Failure, Vol. 8, Núm. 5, pp. 3512-3520

  3. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF

    JACC: Heart Failure, Vol. 9, Núm. 4, pp. 268-277